Krauze A V, Zhuge Y, Zhao R, Tasci E, Camphausen K
Center for Cancer Research, National Cancer Institute, NIH, Building 10, Room B2-3637, Bethesda, USA.
University of British Columbia, Faculty of Medicine, 317 - 2194 Health Sciences Mall, Vancouver, Canada.
J Biotechnol Biomed. 2022;5(1):1-19. doi: 10.26502/jbb.2642-91280046. Epub 2022 Jan 10.
The interpretation of imaging in medicine in general and in oncology specifically remains problematic due to several limitations which include the need to incorporate detailed clinical history, patient and disease-specific history, clinical exam features, previous and ongoing treatment, and account for the dependency on reproducible human interpretation of multiple factors with incomplete data linkage. To standardize reporting, minimize bias, expedite management, and improve outcomes, the use of Artificial Intelligence (AI) has gained significant prominence in imaging analysis. In oncology, AI methods have as a result been explored in most cancer types with ongoing progress in employing AI towards imaging for oncology treatment, assessing treatment response, and understanding and communicating prognosis. Challenges remain with limited available data sets, variability in imaging changes over time augmented by a growing heterogeneity in analysis approaches. We review the imaging analysis workflow and examine how hand-crafted features also referred to as traditional Machine Learning (ML), Deep Learning (DL) approaches, and hybrid analyses, are being employed in AI-driven imaging analysis in central nervous system tumors. ML, DL, and hybrid approaches coexist, and their combination may produce superior results although data in this space is as yet novel, and conclusions and pitfalls have yet to be fully explored. We note the growing technical complexities that may become increasingly separated from the clinic and enforce the acute need for clinician engagement to guide progress and ensure that conclusions derived from AI-driven imaging analysis reflect that same level of scrutiny lent to other avenues of clinical research.
一般而言,医学影像学的解读,尤其是肿瘤学领域的影像学解读,仍然存在问题,原因在于存在若干局限性,包括需要纳入详细的临床病史、患者及疾病特异性病史、临床检查特征、既往及正在进行的治疗,以及考虑到对多个因素的可重复人工解读的依赖性,且数据关联不完整。为了使报告标准化、减少偏差、加快治疗管理并改善治疗结果,人工智能(AI)在影像学分析中的应用已变得极为突出。在肿瘤学中,因此已在大多数癌症类型中探索了人工智能方法,在将人工智能用于肿瘤治疗的影像学、评估治疗反应以及理解和传达预后方面不断取得进展。然而,由于可用数据集有限、随着时间推移成像变化的变异性以及分析方法日益增加的异质性,挑战依然存在。我们回顾了影像学分析工作流程,并研究了手工特征(也称为传统机器学习(ML))、深度学习(DL)方法和混合分析,是如何在中枢神经系统肿瘤的人工智能驱动的影像学分析中得到应用的。ML、DL和混合方法并存,它们的结合可能会产生更好的结果,尽管该领域的数据尚属新颖,结论和陷阱尚未得到充分探索。我们注意到技术复杂性不断增加,这可能会与临床日益脱节,并迫切需要临床医生参与以指导进展,并确保从人工智能驱动的影像学分析得出的结论反映出与其他临床研究途径相同程度的严格审查。